Novartis: Goldman Sachs still a buyer after results
(CercleFinance.com) - The Swiss Healthcare Group has reported Q2 core EPS of 1.
36 dollar and core operating income of 3.7 billion dollars, up 1% as reported and up 6% at constant exchange rates.
Following this publication, the broker confirmer its buy rating on the stock, with a target price of 110 Swiss francs.
Goldman Sachs deems that this morning Novartis published in line Q2 2020 results. Net sales were 11.3 billion dollars, down 4% as reported and 1% at constant exchange rates.
"Core operating income (6% growth) came in 1% ahead of Consensus, reflecting lower spending and improved gross margin, driven by product mix," Goldman Sachs said.
"For Core products, while Entresto sales of $580m came 4% ahead of expectations, Cosentyx sales of $944m came 2% below Consensus. Sandoz were particularly impacted, especially in April and May, although the company is seeing signs of recovery from the second half of the quarter," it adds.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.